NeurAxon Inc., based in Toronto, is a CNS research and development company dedicated to satisfying the growing and unmet need for chronic pain management. The company is a spin-off of Toronto-based chemistry CRO, MCR Research. Their strategy is to discover, develop and commercialize novel and patentable small molecules that interact with established, yet unexploited, molecular targets known to act in multiple pain systems. NeurAxon is focused on developing pain therapeutics targeting neuronal Nitric Oxide Synthase (nNOS) inhibitors.

For more information visit: http://www.nrxn.com/